Global Late Stage Chronic Kidney Disease Drugs Market Landscape: Trends and Market Share to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Forecasted Growth Rate and Market Size of the Late Stage Chronic Kidney Disease Drugs Market?
There has been substantial growth in the market size for late stage chronic kidney disease drugs in recent years. The value is expected to surge from $7.08 billion in 2024, to $7.86 billion in 2025, indicating a compound annual growth rate (CAGR) of 11.1%. Numerous factors account for the growth experienced in the historic period, such as enhanced diagnostic resources, growing elderly population, a rise in diabetes and hypertension cases, increased awareness about kidney diseases, and the broadening scope of pharmaceutical research and development.
The market for late stage chronic kidney disease drugs is set to witness remarkable growth in the upcoming years, projecting it to reach a valuation of ” $12.11 billion in 2029 with a compound annual growth rate (CAGR) of 11.4%. The anticipated surge in this period is attributed to an increase in healthcare spending, the uptake of precision medicine methods, a heightened focus on regenerative medicine, a rising accentuation on patient-desired care, and global kidney disease awareness initiatives. The forthcoming period is likely to see trends like the broadening of regenerative medicine therapies, the upward trajectory of telemedicine services for managing CKD, the creation of combined therapy solutions, emphasis on strategies for early intervention, and growing fascination in biomarker-based diagnostics.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12196&type=smp
Which Factor Is Shaping The Future Of The Late Stage Chronic Kidney Disease Drugs Market?
The late-stage chronic kidney disease drug market is forecasted to grow due to the widespread occurrence of chronic kidney diseases. Chronic kidney ailments encompass various conditions that impair the kidneys’ structure and function. Medicines for late-stage chronic kidney disease work to manage blood pressure and minimize protein loss, thus slowing kidney disease progression, managing symptoms and preventing adverse outcomes. As an illustration, the Centers for Disease Control and Prevention (CDC), a health agency based in the US, reported in May 2024 that roughly 14% of U.S. adults, equivalent to about 35.5 million people, are thought to be living with chronic kidney diseases. Thus, this high prevalence is fueling the expansion of the market for late-stage chronic kidney disease drugs.
The late stage chronic kidney disease drugs market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
What Notable Trends Are Shaping The Direction Of The Late Stage Chronic Kidney Disease Drugs Market?
The emergence of product innovation as a leading trend in the late-stage chronic kidney disease drug market is gaining prominence. Major players in this market are churning out innovative drug products to cement their market position. For instance, Bayer, a pharmaceutical and biotechnology corporation based in Germany, introduced a new product, Kerendia (finerenone), to the Indian market in February 2022. Finerenone, a first-class non-steroidal and selective mineralocorticoid receptor antagonist, is recommended for type two diabetes and chronic renal disease patients. It operates by inhibiting excessive activation of the mineralocorticoid receptor, which is believed to contribute to the development of chronic kidney disease and cardiovascular damage.
Which Companies Hold The Largest Market Share In The Late Stage Chronic Kidney Disease Drugs Sector?
Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc
How Does Regional Performance Compare Across The Late Stage Chronic Kidney Disease Drugs Industry?
North America was the largest region in the late-stage chronic kidney disease drugs market in 2024. The regions covered in the late-stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12196&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
